|
More bad news for Novartis on heart failure candidate
PMLiVE Prospects for Novartis’ acute heart failure (AHF) drug serelaxin look increasingly dim after FDA reviewers recommended against approval ahead of an advisory committee meeting tomorrow. The reviewers recommend (PDF) that the drug “not be approved at … |
|
AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney …
News-Medical.net AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which … AM-Pharma Announces Phase 1 AKI Drug DataDrug Discovery & Development |
|
FDA Staff Recommends Rejection of Novartis Heart-Failure Drug
Wall Street Journal The FDA’s medical review said the data didn’t show serelaxin slowed progress of heart failure nor did it “provide persuasive evidence of an effect” on shortness of breath, a main heart-failure symptom. The unusually negative review from FDA staff doesn … |
News Tonight Africa |
UPDATE 2-FDA staff review recommends against Novartis heart failure drug
Reuters “We recommend that serelaxin not be approved at this time because there is insufficient evidence to support the proposed indication to “improve the symptoms of acute heart failure through reduction of the rate of worsening of heart failure,” the … FDA Reviewers Recommend Against Approval For Novartis Heart Failure DrugForbes FDA Staff Recommends Rejection of Novartis Heart-Failure DrugWall Street Journal More bad news for Novartis on heart failure candidatePMLiVE GlobalPost all 28 news articles » |
Headlines & Global News |
FDA Reviewers Recommend Against Approval For Novartis Heart Failure Drug
Forbes On Thursday the FDA’s Cardiovascular and Renal Drugs Advisory Committee will discuss the biologics license application (BLA) for serelaxin injection (proposed trade name Reasanz) from Novartis. The indication is for the improvement of the symptoms of … FDA staff review recommends against Novartis heart failure drugReuters India |
News Tonight Africa |
FDA staff review recommends against Novartis heart failure drug
Reuters “We recommend that serelaxin not be approved at this time because there is insufficient evidence to support the proposed indication to “improve the symptoms of acute heart failure through reduction of the rate of worsening of heart failure,” the report … FDA Reviewers Recommend Against Approval For Novartis Heart Failure DrugForbes FDA Rejects Approval of Novartis drug Serelaxin for Heart FailureNews Tonight Africa FDA Staff Recommends Against Approval For Novartis’ Heart-failure Drug …NASDAQ FierceBiotech all 28 news articles » |
|
Coroner: Bucks inmate died of heart failure during heroin withdrawal
Bucks County Courier Times A 49-year-old Bensalem woman found dead inside her Bucks County prison cell suffered sudden cardiac death during heroin detoxification, according to the Bucks County coroner. Marlene Yarnall was found dead in her cell in the “F” module of the prison … |
The Malaysian Insider |
Activist Irene Fernandez suffers heart failure, in critical condition, says sister
The Malaysian Insider Prominent activist Irene Fernandez (pic) is in critical condition at the Serdang Hospital after suffering heart failure while on her way to attend the release of the findings of the Bersih’s People Tribunal on the 13th general election this morning … Tenaganita’s Irene Fernandez suffers heart failureThe Star Online |
Study: Algorithm uses activity, breathing data to predict heart failure eventsmobihealthnewsheart failure A non-randomized, double-blind study of 521 patients with heart failure found that the combination of data from minute ventilation and physical ac…
WJXT Jacksonville |
New device could save people with heart failure
WJXT Jacksonville Heart failure is the fastest growing cardiovascular disorder in the U.S., affecting more than six-million people. It occurs when a person’s heart is too weak to pump and circulate blood in the body. However, now a new device that gets on your nerves … |